Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)


Creative Commons License

Garassino M., Paz-Ares L., Hui R., Faivre-Finn C., Spira A., Planchard D., ...Daha Fazla

Annals of Oncology, cilt.30, 2019 (SCI-Expanded, Scopus)